MSCV-Myc-PGK-Puro-IRES-GFP Citations (2)

Originally described in: Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition.
Hohmann AF, Martin LJ, Minder JL, Roe JS, Shi J, Steurer S, Bader G, McConnell D, Pearson M, Gerstberger T, Gottschamel T, Thompson D, Suzuki Y, Koegl M, Vakoc CR Nat Chem Biol. 2016 Jul 4. doi: 10.1038/nchembio.2115. PubMed Journal

---

Articles Citing MSCV-Myc-PGK-Puro-IRES-GFP

Articles
Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer. Zhang S, Iyer S, Ran H, Dolgalev I, Gu S, Wei W, Foster CJR, Loomis CA, Olvera N, Dao F, Levine DA, Weinberg RA, Neel BG. Cancer Discov. 2021 Feb;11(2):362-383. doi: 10.1158/2159-8290.CD-20-0455. Epub 2020 Nov 6. PubMed
Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy. Iyer S, Zhang S, Yucel S, Horn H, Smith SG, Reinhardt F, Hoefsmit E, Assatova B, Casado J, Meinsohn MC, Barrasa MI, Bell GW, Perez-Villatoro F, Huhtinen K, Hynninen J, Oikkonen J, Galhenage PM, Pathania S, Hammond PT, Neel BG, Farkkila A, Pepin D, Weinberg RA. Cancer Discov. 2021 Feb;11(2):384-407. doi: 10.1158/2159-8290.CD-20-0818. Epub 2020 Nov 6. PubMed

If you have published an article using this material, please email us at to have your article added to this page.